Q4 first patient dosed...means it will be 3 years since we got prelim results of the Phase IIA. Biotechs can be sooo slow. The fact that we're going to be more than 3 years between last patient dosed for Phase IIA and first patient dosed for Phase IIB -- when these boys only live to be in theirs 20s -- is frustrating. They need to figure out a way to speed up these processes.
Ann: ATL1102 DMD Clinical Trial Application Submitted in Europe, page-58
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
